Rafael Amado
Executive Vice President of Research and Development and Chief Medical Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Allogene Therapeutics, Inc. (ALLO) | Former Executive Vice President of Research and Development | $633,627 | $5,244,710 |
| 2021 | Allogene Therapeutics, Inc. (ALLO) | Former Executive Vice President of Research and Development | $571,591 | $9,714,156 |
| 2020 | Allogene Therapeutics, Inc. (ALLO) | Former Executive Vice President of Research and Development | $510,000 | $2,663,819 |
| 2019 | Allogene Therapeutics, Inc. (ALLO) | Chief Medical Officer and Executive Vice President of Research and Development | $145,833 | $7,452,158 |
Executive changes
Earnings-call appearances
-
Allogene Therapeutics, Inc. Q3 FY2022 Earnings Call2022-11-02
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q2 FY2022 Earnings Call2022-08-09
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q1 FY2022 Earnings Call2022-05-04
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q4 FY2021 Earnings Call2022-02-23
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q3 FY2021 Earnings Call2021-11-04
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q2 FY2021 Earnings Call2021-08-04
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q1 FY2021 Earnings Call2021-05-05
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q4 FY2020 Earnings Call2021-02-25
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q3 FY2020 Earnings Call2020-11-04
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q2 FY2020 Earnings Call2020-08-05
Allogene Therapeutics, Inc. (ALLO)
-
Allogene Therapeutics, Inc. Q1 FY2020 Earnings Call2020-05-06
Allogene Therapeutics, Inc. (ALLO)